.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
China's drug regulator recently announced a landmark decision regarding neural technology. They granted the world's first commercial BCI medical device approval. This innovative system helps patients with quadriplegia regain hand-grasping abilities. Borui Kang Medical Technology developed this invasive device. It uses electrodes placed directly onto the brain via minimally invasive extradural implantation.
The approval marks a significant shift in global neuro-technology regulation. Doctors can now offer this advanced wireless technology to eligible patients. Consequently, individuals with cervical spinal cord injuries may see a vastly improved quality of life. The system specifically targets adults between 18 and 60 years old. Furthermore, patients must have a stable condition for at least six months post-injury. This stability ensures the safest and most effective outcomes during the recovery phase.
Eligible candidates for the device must demonstrate a total lack of hand-grasping function. However, they must still retain some residual upper-arm movement. Additionally, clinical trials showed significant gains in motor control among participants. Therefore, the National Medical Products Administration has prioritized the development of these sectors. Beijing officially designated brain-computer interfaces as a core future industry in its latest plan. Experts believe BCI technology will move into practical public use within five years. As a result, this approval sets a historic global regulatory precedent for neuro-prosthetics.
Q1: Who is eligible for this new BCI treatment?
Patients aged 18 to 60 with cervical spinal cord injuries leading to quadriplegia are the primary candidates for this device.
Q2: How does the invasive BCI system function?
The device uses minimally invasive extradural electrodes and wireless technology to record brain signals and translate them into physical hand movements.
Q3: What are the clinical requirements before implantation?
The diagnosis must be at least one year old, and the patient must have been in a stable condition for six months following standard treatment.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
China’s drug regulator has approved the world’s first commercial brain-computer interface (BCI) system to restore hand-grasping ability in paralyzed patient...
5 months ago
A new case study illuminates how functional connectivity changes drive recovery from pure alexia following posterior cerebral artery infarction. Functional reorganization supports reading recovery despite permanent structural tract disconnection, highlighting key implications for stroke rehabilitation.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
